{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.58","upperLimit":"86.14","value":"61.54"},{"groupId":"OG001","lowerLimit":"13.86","upperLimit":"68.42","value":"38.46"},{"groupId":"OG002","lowerLimit":"31.58","upperLimit":"86.14","value":"61.54"},{"groupId":"OG003","lowerLimit":"13.86","upperLimit":"68.42","value":"38.46"},{"groupId":"OG004","lowerLimit":"38.54","upperLimit":"80.29","value":"60.87"},{"groupId":"OG005","lowerLimit":"49.17","upperLimit":"84.72","value":"68.97"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"description":"Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Will report the percentage of patients within each disease stratum who experienced a grade 3 or higher toxicity with attribution of possible, probable, or definite while on protocol therapy or within 30 days of the last dose of therapy","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Ewing's Sarcoma"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Rhabdomyosarcoma"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Non-Rhabdomyosarcoma Soft Tissue Sarcoma"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Wilms Tumor"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Rare Tumors"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Osteosarcoma"}],"paramType":"NUMBER","populationDescription":"All patients who met the evaluable for toxicity criteria outlined in section 9.5 of the ADVL1622 protocol.","reportingStatus":"POSTED","timeFrame":"Up to 5 years (duration of protocol therapy plus 30 days after last dose of therapy)","title":"Percentage of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}